Research on protection against influenza viral infection using human monoclonal antibody

我们建立的人单克隆抗体（HuMAb） 5A7识别了乙型流感病毒（FluB）中一个高度保守的血凝素（HA）区域。5A7广泛中和FluB，在小鼠中显示出显著的治疗效果。这些结果表明，5A7为研制抗乙型流感的通用疫苗提供了新的思路。此外，我们还通过中和A(H1N1)pdm09 HA蛋白中识别抗原位点Sb的HuMAb 5E4，研究了A(H1N1)pdm09的多样性。与2009/10年样品相比，2010/11年样品对5E4的中和效价显著降低。在2009/10和2010/11之间，Sb序列被正选择。在GenBank中，抗原位点Sb的变异在全球范围内显著增加，表明Sb的抗原变异目前可能在全球流通。

Our established human monoclonal antibody (HuMAb) 5A7 recognized a highly conserved regionof hemagglutinin (HA) in influenza B viruses (FluB). 5A7 broadly neutralized FluB and showed significant therapeutic efficacy in mice. These results indicate that 5A7 provides insight for the development of a universal vaccine against FluB. Also we studied the diversity of A(H1N1)pdm09 using neutralizing HuMAb 5E4 recognizing antigenic site Sb in the HA protein of A(H1N1)pdm09. Neutralization titers were significantly reduced against 5E4 in the 2010/11 compared with the 2009/10 samples. Sequences in Sb were being positively selected between 2009/10 and 2010/11. Variants in the antigenic site Sb increased significantly worldwide from GenBank, indicating that the antigenic variants in Sb are likely to be in global circulation currently.